Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “C3 Glomerulopathy (C3G)”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Testing effectiveness (Phase 2)Looking for participantsNCT06209736
What this trial is testing

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

Who this might be right for
C3 GlomerulopathyIdiopathic Immune Complex-Mediated Glomerulonephritis
Omeros Corporation 20
Large-scale testing (Phase 3)Looking for participantsNCT03955445
What this trial is testing

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Who this might be right for
C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals 225
Not applicableLooking for participantsNCT07029542
What this trial is testing

Home Reported Outcomes in C3G Study

Who this might be right for
C3 Glomerulopathy
Novartis Pharmaceuticals 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04572854
What this trial is testing

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Who this might be right for
C3GIC-MPGNRenal Transplant+9 more
Apellis Pharmaceuticals, Inc. 13
Not applicableApproved For MarketingNCT04729062
What this trial is testing

C3G/Primary IC-MPGN EAP

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc.
Not applicableNot Yet RecruitingNCT07331259
What this trial is testing

CHART-C3G/CLNP023B12011

Who this might be right for
C3 GlomerulopathyComplement-mediated Kidney DiseaseProteinuria
Novartis Pharmaceuticals 83
Testing effectiveness (Phase 2)Ended earlyNCT03459443
What this trial is testing

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Alexion Pharmaceuticals, Inc. 22
Early research (Phase 1)WithdrawnNCT02302755
What this trial is testing

TP10 Use in Patients With C3 Glomerulopathy (C3G)

Who this might be right for
Dense Deposit Disease
University of Iowa
Not applicableStudy completedNCT03723512
What this trial is testing

Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study

Who this might be right for
C3 GlomerulonephritisC3 GlomerulopathyImmune Complex Membranoproliferative Glomerulonephritis+2 more
Mario Negri Institute for Pharmacological Research 7
Testing effectiveness (Phase 2)WithdrawnNCT06419205
What this trial is testing

Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Who this might be right for
IgA NephropathyLupus Nephritis (LN)C3 (Complement Component 3) Glomerulopathy
Q32 Bio Inc.
Not applicableLooking for participantsNCT07156149
What this trial is testing

Fabhalta Capsules Specified Drug-use Survey

Who this might be right for
C3 Glomerulopathy
Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)Study completedNCT03301467
What this trial is testing

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

Who this might be right for
C3 Glomerulopathy (C3G)
Amgen 57
Testing effectiveness (Phase 2)Study completedNCT03369236
What this trial is testing

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Who this might be right for
C3 GlomerulopathyC3 GlomerulonephritisDense Deposit Disease
Alexion Pharmaceuticals, Inc. 13
Large-scale testing (Phase 3)Active Not RecruitingNCT05809531
What this trial is testing

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc. 100
Testing effectiveness (Phase 2)Study completedNCT03124368
What this trial is testing

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

Who this might be right for
C3 GlomerulonephritisDense Deposit DiseaseC3 Glomerulopathy+2 more
Alexion Pharmaceuticals, Inc. 6
Early research (Phase 1)Study completedNCT03316521
What this trial is testing

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Who this might be right for
Complement Mediated Diseases
Amyndas Pharmaceuticals S.A. 50
Large-scale testing (Phase 3)Study completedNCT05067127
What this trial is testing

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Who this might be right for
C3GIC-MPGNC3 Glomerulopathy+9 more
Apellis Pharmaceuticals, Inc. 124
Large-scale testing (Phase 3)Looking for participantsNCT04817618
What this trial is testing

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Who this might be right for
C3G
Novartis Pharmaceuticals 98
Not applicableAvailableNCT05222412
What this trial is testing

Managed Access Programs for LNP023, Iptacopan

Who this might be right for
C3 Glomerulopathy (C3G)Paroxysmal Nocturnal Hemoglobinuria (PNH)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05647811
What this trial is testing

Study of NM8074 in Adult C3 Glomerulopathy Patients

Who this might be right for
C3 Glomerulopathy
NovelMed Therapeutics 18